Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity

Fig. 3

PD-1 blocked CAR-T cells demonstrated impaired anti-tumor effects in vivo. a A549–19luc xenograft model was established by subcutaneously injection of 5 × 106 tumor cells per mouse. And then, the tumor bearing mice were treated with different CAR-T cells or non-infected T cells as control. S4-CART19 did not show better anti-tumor function than SCR-CART19. b Average fluorescence intensity in each mouse was measured to study the tumor burden, and the changes of tumor burden within 4 weeks after CAR-T reinfusion were presented here. SCR-CART19 inhibited the tumor growth more obviously. c The percentage of CD3 positive T cells was used to evaluate the number of CAR-T cells. And the data for each mouse within 4 weeks after CAR-T reinfusion indicated that the amplification of CAR-T was not obvious in this model. d Survival curves were analyzed using the log-rank test, and the statistical result did not prove that there was a significant difference between SCR-CART19 and S4-CART19 treated mice. Data are plotted as individual points

Back to article page